Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Janssen submits US FDA new drug application for simeprevir / sofosbuvir combination use

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc. This regulatory submission is for the treatment of genotype 1 chronic hepatitis C (HCV) in adult treatment-naive patients with advanced fibrosis and null responders with all stages of liver fibrosis.

Published
08 May 2014
From
Janssen press release
UNITAID approves grants of $160 million, for hepatitis C, MDR-TB and malaria drugs

Breakthrough new medicines for hepatitis C and drug-resistant TB and largest-yet global programme for seasonal malaria chemoprevention to be made available for low- and middle-income countries as part of $160 million of new grants funded by UNITAID

Published
07 May 2014
From
UNITAID
UK - 'Eradicating hepatitis C is a realistic aim'

New highly effective drugs have created the potential for the eradication of hepatitis C, says Stephen Ryder and John Dillon, but the NHS must clear several hurdles to reach this goal.

Published
06 May 2014
From
Health Service Journal
Sustained response to treatment reduces fatigue in hepatitis C patients

Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according

Published
06 May 2014
By
Liz Highleyman
Vertex ends hepatitis C investment as sales fall

Vertex Pharmaceuticals, which reported more than $1 billion in sales of its hepatitis C drug Incivek in 2012, said Thursday it won't invest any more money on research and development of new treatments for the disease.

Published
02 May 2014
From
CNBC
Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4

A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus genotype 4, though treatment for only 12 weeks was not

Published
02 May 2014
By
Liz Highleyman
Hepatitis B a growing problem in UK prisons

In a written answer to a parliamentary question, Health Minister Norman Lamb said the number of prisoners diagnosed with chronic forms of the virus has risen from just 22 in 2010 to 109 in 2013.

Published
01 May 2014
From
The Independent
Eliminating Hepatitis C Within a Generation. What are you going to do about it?

Videos from a symposium organised by the London Joint Working Group on Substance Use and Hepatitis C.

Published
30 April 2014
From
You Tube / Jon Derricott
Biotech’s Hard Bargain

Investors love drug companies in part because they often have tremendous pricing power. Drugs designed to fight rare diseases routinely cost two or three hundred thousand dollars; cancer drugs often cost a hundred grand. But the signs of a backlash are clear.

Published
24 April 2014
From
The New Yorker
Anti-HBV antiretrovirals may help ward off HBV infection in MSM

Three antiretrovirals that also help control hepatitis B virus (HBV) infection—tenofovir, emtricitabine, and lamivudine—may also prevent HBV infection, according to results of a retrospective analysis involving men who have sex with men (MSM) in the Netherlands.

Published
24 April 2014
From
International AIDS Society

Filter by country